A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)

An Open-label, Multicenter, Phase 4 Study to Assess the Effects of a Prophylactic Immune Tolerizing Regimen in MPS II Treatment-Naïve Patients Planned to Receive ELAPRASE Who Are at Risk of Developing Persistent Neutralizing Antibodies

The main aim of this study is to evaluate the ability of a prophylactic immune tolerizing regimen (ITR) to prevent or reduce the development of high titer anti-idursulfase antibodies in treatment-naïve participants with Hunter syndrome.

In this open label, single arm study, all participants will receive ELAPRASE treatment and a prophylactic ITR.

Participants will be treated with ELAPRASE for up to 104 weeks. The prophylactic ITR will start 1 day prior to the start of ELAPRASE. The prophylactic ITR will consist of a 5-week cycle of: Rituximab (intravenously [IV], weekly for 4 weeks); Methotrexate (oral, 3 times per week for 5 weeks) and intravenous immunoglobulin (IVIG) (IV, every 4 weeks of the cycle).

Following the completion of 1 cycle, an assessment will be made at Month 6, 12, and 18 regarding the need for administering another 5-week cycle of the ITR.

Participants will be in the study for approximately 112 weeks (including 6 weeks for screening, up to 104 weeks for treatment, and 2 weeks for follow-up).

Study Overview

• Status: Recruiting
• Conditions: Hunter Syndrome; Mucopolysaccharidosis (MPS)
• Intervention / Treatment: Drug: ELAPRASE; Drug: Rituximab; Drug: Methotrexate; Drug: Intravenous Immunoglobulin (IVIG)

• Study Type: Interventional
• Enrollment (Estimated): 5
• Phase: Phase 4

Contacts and Locations

• Study Contact: Name: Takeda Contact; Phone Number: +1-877-825-3327; Email: medinfoUS@takeda.com

Study Locations

• United States
  • Arizona
    • Phoenix, Arizona, United States, 85016
      • Recruiting
      • Phoenix Childrens Hospital
      • Contact: Site Contact
      • Principal Investigator: Gerard Vockley
  • California
    • Oakland, California, United States, 94609
      • Recruiting
      • Children's Hospital and Research Center at Oakland
      • Contact: Site Contact; Phone Number: 510-428-3058; Email: paul.harmatz@ucsf.edu
      • Principal Investigator: Paul Harmatz
    • Sacramento, California, United States, 95817
      • Not yet recruiting
      • UC Davis Medical Center
      • Contact: Site Contact; Phone Number: 916-703-0346; Email: bcgmartin@ucdavis.edu
      • Principal Investigator: Madelena Martin
    • San Diego, California, United States, 92123
      • Recruiting
      • Rady Childrens Hospital San Diego - PIN
      • Contact: Site Contact; Phone Number: 858-966-8508; Email: rmardach@health.ucsd.edu
      • Principal Investigator: Rebecca Mardach
    • Torrance, California, United States, 90502
      • Recruiting
      • The Lundquist Institute for BioMedical Innovation at Harbor-UCLA Medical Center
      • Contact: Site Contact; Phone Number: 310-222-1961; Email: lpolgreen@labiomed.org
      • Principal Investigator: Lynda Polgreen
  • Illinois
    • Chicago, Illinois, United States, 60611
      • Not yet recruiting
      • Ann and Robert H Lurie Childrens Hospital of Chicago
      • Contact: Site Contact; Phone Number: 312-227-6120; Email: bburton@luriechildrens.org
      • Principal Investigator: Barbara Burton
  • Minnesota
    • Minneapolis, Minnesota, United States, 55404
      • Recruiting
      • Children's Hospitals and Clinics of Minnesota
      • Contact: Site Contact; Phone Number: 612-813-7240; Email: vikas.bhambhani@childrensmn.org
      • Principal Investigator: Vikas Bhambhani
  • New York
    • New York, New York, United States, 10032
      • Not yet recruiting
      • NewYork-Presbyterian Morgan Stanley Children's Hospital
      • Contact: Site Contact; Phone Number: 212-305-3647; Email: gm3025@cumc.columbia.edu
      • Principal Investigator: Gustavo Maegawa
  • North Carolina
    • Chapel Hill, North Carolina, United States, 27599
      • Not yet recruiting
      • University of North Carolina at Chapel Hill
      • Contact: Site Contact; Phone Number: 919-966-1447; Email: muenzer@med.unc.edu
      • Principal Investigator: Joseph Muenzer
  • Ohio
    • Twinsburg, Ohio, United States, 44087
      • Not yet recruiting
      • The Cleveland Clinic Foundation
      • Contact: Site Contact; Phone Number: 216-445-7862; Email: hannar2@ccf.org
      • Principal Investigator: Rabi Hanna
  • Pennsylvania
    • Pittsburgh, Pennsylvania, United States, 15224
      • Not yet recruiting
      • Children's Hospital of Pittsburgh
      • Contact: Site Contact; Phone Number: 412-692-5194; Email: damara.ortiz@chp.edu
      • Principal Investigator: Damara Ortiz

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: No older than 6 years (Child)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Participant is male.
• Participant is ELAPRASE-naïve at study entry.

• Participant must have a documented diagnosis of MPS II. The following combination will be accepted as diagnostic of MPS II:

  • Participant has a deficiency in iduronate-2-sulfatase (I2S) enzyme activity of less than or equal to (<=) 10 percent (%) of the lower limit of the normal range as measured in plasma, fibroblasts, or leukocytes (based on the reference laboratory's normal range). The participant has a normal enzyme activity level of at least 1 other sulfatase as measured in plasma, fibroblasts, or leukocytes (based on the reference laboratory's normal range).
  • Participant has a documented mutation in the IDS gene; additionally, participants must have a severe mutation (example, large deletion or complex gene rearrangement), which is predicted to lead to development of a persistent anti-idursulfase antibody response.
• Participant will be less than (<) 6 years of age at enrollment.
• Participant has a negative test result for serum anti-idursulfase antibodies.

Exclusion Criteria:

• Participant has received treatment with any investigational drug within the 30 days prior to study entry.
• Participant has received or is receiving treatment with idursulfase-IT.
• Participant has received growth hormones, a cord blood infusion, or a bone marrow transplant at any time.
• Participant has received blood product transfusions within 90 days prior to screening.
• Participant is unable to comply with the protocol as determined by the investigator.
• Participant has known or suspected intolerance or hypersensitivity to the investigational product(s), closely related compounds, or any of the stated ingredients, including the prophylactic ITR.
• Participant has current or recurrent disease that could affect the action, absorption, or disposition of the investigational product, or clinical or laboratory assessments.
• Participant has current or relevant history of physical or psychiatric illness, or any medical disorder that may require treatment or make the participant unlikely to fully complete the study, or any condition that presents undue risk from the investigational product or procedures.
• Participant has current use of any medication (including over-the-counter, herbal, or homeopathic preparations) that could affect (improve or worsen) the condition being studied, or could affect the action, absorption, or disposition of the investigational product(s), or clinical or laboratory assessment (Current use is defined as use within 30 days).
• Within 30 days prior to the first dose of investigational product, the participant has been enrolled in a clinical study (including vaccine studies) that, in the investigator's opinion, may impact this study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: ITR + ELAPRASE; Participants will receive prophylactic ITR which consist of rituximab, methotrexate and IVIG in a 5-week cycle. Following the completion of 1 cycle and at the Month 6, 12, and 18 study visits, an assessment will be made regarding the need for administering another 5-week cycle of the ITR depending on the trend of the participants anti-idursulfase antibody titers and lymphocyte quantitation and CD19 percent (%) recovery. Elaprase treatment (IV, weekly) will start 1 day after the initiation of the first cycle of ITR and continue for 104 weeks. The dose of ELAPRASE will be calculated based on the participant's weight at each visit.

Drug: ELAPRASE; Participants will receive 0.5 milligram per kilogram (mg/kg) of body weight of ELAPRASE, intravenous, infusion for 104 weeks.; Other Names: Idursulfase; Drug: Rituximab; Participants will receive 375 milligram per square meter per dose (mg/m^2/dose) of intravenous rituximab weekly for 4 weeks in 5-week cycle.; Drug: Methotrexate; Participants will receive 0.4 mg/kg of methotrexate by mouth (PO) 3 times per week for 5 weeks in each cycle.; Drug: Intravenous Immunoglobulin (IVIG); Participants will receive 500 mg/kg of IVIG every 4 weeks in 5-week cycle.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Rate of Anti-Idursulfase Antibodies Formation, Including Anti-Idursulfase Antibodies That Have Enzyme Neutralizing Activity	Serum samples will be collected for evaluation of anti-idursulfase antibodies including binding antibodies and neutralizing antibodies. Analysis of anti-idursulfase antibodies will be conducted using validated 3-tier immunoassay methods. Rate will be defined as the number of participants having positive antibodies compared to the total number of participants.	Up to 24 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Correlation Between Anti-drug Antibody (ADA) Responses and Iduronate-2-Sulfatase (IDS) Gene Mutations and Clinical Outcomes	Correlation between ADA responses and IDS gene mutations and clinical outcomes (efficacy and safety) every 6 months in comparison to historical results from Study SHPELA- 401 (NCT02455622) without immune tolerance treatment will be reported. Analysis of covariance will be performed to correlate ADA response, IDS gene mutation and clinical outcomes.	Every 6 months up to 24 months
Change From Baseline in Urinary Glycosaminoglycan (uGAG) Levels Normalized to Urine Creatinine	Urine samples will be collected for the determination of uGAG levels and urine creatinine monthly prior to dosing. Change from baseline in uGAG levels normalized to urine creatinine will be reported.	Up to 24 months
Change From Baseline in Normalized uGAG per Upper Limit of Normal for age (uGAG)/ULN)	Urine samples will be collected for the determination of uGAG levels monthly prior to dosing. Change from baseline in normalized uGAG/ULN will be reported.	Up to 24 months
Change From Baseline in Liver Volume	Liver volume will be measured using abdominal ultrasonography. Change from baseline values for liver volume will be reported.	Up to 24 months

Collaborators and Investigators

• Sponsor: Takeda
• Collaborators: Takeda Development Center Americas, Inc.
• Investigators: Study Director: Study Director, Takeda

Publications and helpful links

Helpful Links

• To obtain more information on the study, click here/on this link

Study record dates

Study Major Dates

• Study Start (Actual): February 28, 2023
• Primary Completion (Estimated): June 15, 2027
• Study Completion (Estimated): June 15, 2027

Study Registration Dates

• First Submitted: August 8, 2022
• First Submitted That Met QC Criteria: August 8, 2022
• First Posted (Actual): August 10, 2022

Study Record Updates

• Last Update Posted (Actual): September 25, 2023
• Last Update Submitted That Met QC Criteria: September 21, 2023
• Last Verified: September 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Metabolic Diseases; Nervous System Diseases; Neurologic Manifestations; Neurobehavioral Manifestations; Disease; Genetic Diseases, Inborn; Genetic Diseases, X-Linked; Connective Tissue Diseases; Carbohydrate Metabolism, Inborn Errors; Metabolism, Inborn Errors; Lysosomal Storage Diseases; Mucinoses; Mental Retardation, X-Linked; Intellectual Disability; Heredodegenerative Disorders, Nervous System; Syndrome; Mucopolysaccharidosis II; Mucopolysaccharidoses; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Nucleic Acid Synthesis Inhibitors; Enzyme Inhibitors; Antirheumatic Agents; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Antineoplastic Agents, Immunological; Dermatologic Agents; Reproductive Control Agents; Abortifacient Agents, Nonsteroidal; Abortifacient Agents; Folic Acid Antagonists; Antibodies; Immunoglobulins; Immunoglobulins, Intravenous; Rituximab; Methotrexate; gamma-Globulins; Rho(D) Immune Globulin
• Other Study ID Numbers: TAK-665-4003

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: De-identified individual participant data from this particular study will not be shared as there is a reasonable likelihood that individual participants could be re-identified (due to the limited number of study participants)
• IPD Sharing Access Criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/ For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes